|
|
Post by rtmd on Jul 7, 2019 9:50:15 GMT -5
blog.profil.com/blog/the-need-for-speed"After almost 100 years of insulin development, another major milestone in insulin development has been achieved with the 2017 market approval of the first ultra-fast acting insulin...Profil has conducted clinical pharmacology trials with all three ultra-fast insulin formulations." Guess who wasn't mentioned once in the article. Does Mannkind have anyone to bird dog these articles and request corrections?
|
|
|
|
Post by caesar on Jul 7, 2019 10:08:27 GMT -5
The article is 19 months old. Obviously 'Profil' was not interested in including Afrezza. The REAL question should be WHY NOT!
'The Need for Speed' was Posted by Dr. Eric Zijlstra on Dec 1, 2017 3:27:09 PM
|
|
|
|
Post by goyocafe on Jul 7, 2019 10:25:11 GMT -5
blog.profil.com/blog/the-need-for-speed"After almost 100 years of insulin development, another major milestone in insulin development has been achieved with the 2017 market approval of the first ultra-fast acting insulin...Profil has conducted clinical pharmacology trials with all three ultra-fast insulin formulations." Guess who wasn't mentioned once in the article. Does Mannkind have anyone to bird dog these articles and request corrections? Considering that the ADA is sponsoring studies for an ultra rapid insulin, it is not surprising that others won’t acknowledge Afrezza either. I suspect, given the reference to automated, continuous delivery, that inhaled insulin, regardless of its PD/PK profile, cannot be automated and is thus not what the ADA and others want. The fact that Afrezza is owned by a small, non-cartel entity makes its presence even less significant in the eyes of those under the control of BP. The industry has spoken, they’d rather wait for an injectable solution that will make automated delivery possible than to embrace Afrezza today. Heaven help them if that ever comes to fruition and the solution isn’t developed by BP. Imagine the scurry that would create. |
|
|
|
Post by agedhippie on Jul 7, 2019 10:44:11 GMT -5
The article is 19 months old. Obviously 'Profil' was not interested in including Afrezza. The REAL question should be WHY NOT! 'The Need for Speed' was Posted by Dr. Eric Zijlstra on Dec 1, 2017 3:27:09 PM They are a German company so Afrezza is not an option. That and they want an insulin that can be used in an automated delivery system like a closed loop APS so it has to be liquid. |
|
|
|
Post by boca1girl on Jul 8, 2019 7:00:55 GMT -5
I clicked on the doctor’s name and other articles popped up. Here is another article he wrote. Insulin injection: recent improvements and alternatives The most common way for patients with diabetes to self-administer insulin is subcutaneously via a needle injection. Patients with type 1 diabetes require multiple daily injections (MDI), adding up to some 1500 injections per year per patient, to control their glucose level. Also, many patients with type 2 diabetes would benefit from (intensive) insulin therapy to achieve their glycaemic target. Painful insulin injections or fear thereof present a barrier to treatment initiation and long-term adherence in patients. Not surprisingly, research into alternative ways of administering insulin, without the need to break the skin barrier, such as via the oral [1], buccal [2], nasal or pulmonary route, has gained interest for decades. Despite these efforts, research into alternative insulin administration has not yet produced any commercially viable products and subcutaneous injection remains the only option for almost all patients. blog.profil.com/blog/author/dr-eric-zijlstra |
|
|
|
Post by lakon on Jul 13, 2019 0:22:32 GMT -5
Has anyone tried ventilating a dispersion of Afrezza or other Technosphere application? MNKD used insufflation in animal testing. Dry powders of this size and shape act like a gas...
|
|
|
|
Post by mnkdfann on Jul 13, 2019 9:12:59 GMT -5
I clicked on the doctor’s name and other articles popped up. Here is another article he wrote. Insulin injection: recent improvements and alternatives The most common way for patients with diabetes to self-administer insulin is subcutaneously via a needle injection. Patients with type 1 diabetes require multiple daily injections (MDI), adding up to some 1500 injections per year per patient, to control their glucose level. Also, many patients with type 2 diabetes would benefit from (intensive) insulin therapy to achieve their glycaemic target. Painful insulin injections or fear thereof present a barrier to treatment initiation and long-term adherence in patients. Not surprisingly, research into alternative ways of administering insulin, without the need to break the skin barrier, such as via the oral [1], buccal [2], nasal or pulmonary route, has gained interest for decades. Despite these efforts, research into alternative insulin administration has not yet produced any commercially viable products and subcutaneous injection remains the only option for almost all patients. blog.profil.com/blog/author/dr-eric-zijlstraDirect link to entire article: blog.profil.com/blog/insulin-injection-recent-improvements-and-alternativesAfrezza is mentioned in the last section. |
|
|
|
Post by boca1girl on Jul 13, 2019 9:51:31 GMT -5
My impression is that the author has a negative bias toward Afrezza. Some may say realistic, others may say negative.
|
|
